Dr. Reddy's Laboratories
RDY
A$22.93
Share price
1.31%
Change (1 day)
1.09%
Change (1 year)
Categories
Dr. Reddy's Laboratories (RDY) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : A$2.75 Billion
According to Dr. Reddy's Laboratories's latest financial reports the company's total liabilities are A$2.75 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Dr. Reddy's Laboratories - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-03-31 | A$1.96 B | 18.91% |
| 2023-03-31 | A$1.65 B | -8.2% |
| 2022-03-31 | A$1.79 B | 8.12% |
| 2021-03-31 | A$1.66 B | -0.29% |
| 2020-03-31 | A$1.66 B | -3.29% |
| 2019-03-31 | A$1.72 B | -12.94% |
| 2018-03-31 | A$1.98 B | 2.61% |
| 2017-03-31 | A$1.93 B | 23.67% |
| 2016-03-31 | A$1.56 B | -10.96% |
| 2015-03-31 | A$1.75 B | 22.58% |
| 2014-03-31 | A$1.43 B | 16.25% |
| 2013-03-31 | A$1.23 B | 4.71% |
| 2012-03-31 | A$1.17 B | 10.59% |
| 2011-03-31 | A$1.06 B | 17.6% |
| 2010-03-31 | A$0.90 B | -22.62% |
| 2009-03-31 | A$1.16 B | 12.6% |
| 2008-03-31 | A$1.03 B | -18.5% |
| 2007-03-31 | A$1.27 B | -13.61% |
| 2006-03-31 | A$1.47 B | 497.3% |
| 2005-03-31 | A$0.24 B | 46.38% |
| 2004-03-31 | A$0.16 B | 13.8% |
| 2003-03-31 | A$0.14 B | 9.99% |
| 2002-03-31 | A$0.13 B | -54.04% |
| 2001-03-31 | A$0.29 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | A$178.53 B | 6,380.32% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | A$48.88 B | 1,674.55% | 🇮🇱 Israel |
 GlaxoSmithKline GSK | A$92.45 B | 3,256.01% | 🇬🇧 UK |
 Novartis NVS | A$93.51 B | 3,294.37% | 🇨🇭 Switzerland |
 Sanofi SNY | A$94.56 B | 3,332.54% | 🇫🇷 France |